TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 29334920

Group type: EXPERIMENTAL
Intervention: Study site for delivery
Number of subjects: 3243

Group type: EXPERIMENTAL
Intervention: Study site for follow-up visits
Number of subjects: 3243

Group type: EXPERIMENTAL
Intervention: Healthcare facility for sick infants
Number of subjects: 3243
Study: 29335013

Group type: EXPERIMENTAL
Intervention: 12-week YMCA community-based wellness program (FIT for FUNCTION)
Number of subjects: 216

Group type: COMPARATOR
Intervention: Standard YMCA membership
Number of subjects: 216
Study: 29335017

Group type: EXPERIMENTAL
Intervention: Single-port laparoscopy (SPL)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Conventional laparoscopy (CL)
Number of subjects: 0
Study: 29335020

Group type: EXPERIMENTAL
Intervention: Genome-wide SNP genotyping and gene expression profiling of lung tissue samples
Number of subjects: 117

Group type: EXPERIMENTAL
Intervention: Integrative analysis using ensemble statistical and network methods
Number of subjects: 117

Group type: EXPERIMENTAL
Intervention: Top gene identified from integrative analysis
Number of subjects: 117

Group type: EXPERIMENTAL
Intervention: Genes identified with RNA binding activity
Number of subjects: 117

Group type: EXPERIMENTAL
Intervention: Gene identified in network communities with validated disease relevance
Number of subjects: 117
Study: 29335232

Group type: EXPERIMENTAL
Intervention: Mindfulness meditation app
Number of subjects: 0

Group type: COMPARATOR
Intervention: Progressive muscle relaxation app
Number of subjects: 0

Group type: COMPARATOR
Intervention: Usual care (no app)
Number of subjects: 0
Study: 29335234

Group type: EXPERIMENTAL
Intervention: Integrated mHealth platform with patient-held smartcard for storing test results of HIV, HBV, and SCD.
Number of subjects: 0
Study: 29335291

Group type: EXPERIMENTAL
Intervention: Electronic Cigarette Smoking
Number of subjects: 0

Group type: COMPARATOR
Intervention: Single Conventional Cigarette
Number of subjects: 0
Study: 29335333

Group type: EXPERIMENTAL
Intervention: Active treatment (initially pursued)
Number of subjects: 1866

Group type: EXPERIMENTAL
Intervention: Rebleeding
Number of subjects: 1866

Group type: COMPARATOR
Intervention: No active treatment (discontinued after admission)
Number of subjects: 1866
Study: 29335831

Group type: EXPERIMENTAL
Intervention: Inter-hospital transport (IHT) of ARDS patients
Number of subjects: 431

Group type: EXPERIMENTAL
Intervention: Extracorporeal membrane oxygenation treatment
Number of subjects: 431

Group type: EXPERIMENTAL
Intervention: Pressure-controlled ventilation during IHT
Number of subjects: 431

Group type: EXPERIMENTAL
Intervention: Duration and distance of IHT
Number of subjects: 431
Study: 29335895

Group type: EXPERIMENTAL
Intervention: Rilpivirine 25 mg once daily
Number of subjects: 19
Study: 29336016

Group type: EXPERIMENTAL
Intervention: Dupilumab treatment
Number of subjects: 0
Study: 29336179

Group type: EXPERIMENTAL
Intervention: Belimumab therapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Antipneumococcal vaccination
Number of subjects: 0
Study: 29336228

Group type: EXPERIMENTAL
Intervention: MULTI-30 therapeutic interventions
Number of subjects: 0
Study: 29337030

Group type: EXPERIMENTAL
Intervention: Nasal IL-25
Number of subjects: 0
Study: 29338080

Group type: EXPERIMENTAL
Intervention: Cisplatin, gemcitabine, and veliparib (80 mg twice daily on days 1 to 12)
Number of subjects: 17

Group type: COMPARATOR
Intervention: Cisplatin and gemcitabine (600 mg/m2 and 25 mg/m2 respectively)
Number of subjects: 17
Study: 29338731

Group type: EXPERIMENTAL
Intervention: HealthCorps program
Number of subjects: 611

Group type: COMPARATOR
Intervention: Comparison group
Number of subjects: 611
Study: 29338758

Group type: EXPERIMENTAL
Intervention: Vitamin D supplementation (25, 10, or 2 μg of vitamin D3 per day)
Number of subjects: 85

Group type: EXPERIMENTAL
Intervention: Vitamin D status at 6 years of age
Number of subjects: 85
Study: 29338953

Group type: EXPERIMENTAL
Intervention: Gun-related violent crime (1 per 10,000 people)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Homicide rates
Number of subjects: 48
Study: 29339012

Group type: EXPERIMENTAL
Intervention: Phone communication
Number of subjects: 1395

Group type: EXPERIMENTAL
Intervention: Care coordination
Number of subjects: 1395

Group type: EXPERIMENTAL
Intervention: In-person communication
Number of subjects: 1395
Study: 29339202

Group type: EXPERIMENTAL
Intervention: Polished enamel samples exposed to orange juice for 5, 10, or 15 minutes in both in-vivo and ex-vivo conditions.
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Polished enamel samples exposed to orange juice for 30 minutes in both in-vivo and ex-vivo conditions.
Number of subjects: 30
Study: 29339269

Group type: EXPERIMENTAL
Intervention: Intravenous busulfan (9.6 mg/kg) and melphalan (140 mg/m2)
Number of subjects: 99
Study: 29339394

Group type: EXPERIMENTAL
Intervention: Finafloxacin; administered orally
Number of subjects: 127
Study: 29339403

Group type: EXPERIMENTAL
Intervention: Azacitidine combined with chemotherapy
Number of subjects: 0
Study: 29339691

Group type: EXPERIMENTAL
Intervention: Current clinical practice evaluation through a cross-sectional survey
Number of subjects: 2000

Group type: EXPERIMENTAL
Intervention: Cross-sectional survey of public perception and knowledge of cholesterol treatment
Number of subjects: 2000
Study: 29340875

Group type: EXPERIMENTAL
Intervention: TEG-based protocol (target 16-24 min of the R parameter)
Number of subjects: 42

Group type: COMPARATOR
Intervention: aPTT-based protocol (target 1.5-2 of aPTT ratio)
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: TEG-based protocol
Number of subjects: 42

Group type: COMPARATOR
Intervention: aPTT-based protocol
Number of subjects: 42
Study: 29340911

Group type: EXPERIMENTAL
Intervention: Survivors of sexual violence (SV)
Number of subjects: 334

Group type: EXPERIMENTAL
Intervention: Exposure to sexual violence (SV)
Number of subjects: 334
Study: 29341967

Group type: EXPERIMENTAL
Intervention: Inhaled Nitric Oxide (NO) at an initial dose of 10 (10, 15) ppm for adults, 20 (18, 20) ppm for children, and 17 (11, 20) ppm for neonates, administered for a median duration of 3.9 (1.9, 6.1) days for adults, 3.8 (1.8, 6.8) days for children, and 3.1 (1.0, 5.7) days for neonates.
Number of subjects: 236
Study: 29342018

Group type: EXPERIMENTAL
Intervention: MILOS operation
Number of subjects: 615
Study: 29342264

Group type: EXPERIMENTAL
Intervention: Real-time continuous glucose monitoring (RT-CGM)
Number of subjects: 515
Study: 29342267

Group type: EXPERIMENTAL
Intervention: 0.50 mg/kg of SLD-PQ
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: 0.40 mg/kg of SLD-PQ
Number of subjects: 51
Study: 29343131

Group type: EXPERIMENTAL
Intervention: Plecanatide 6 mg
Number of subjects: 2370

Group type: EXPERIMENTAL
Intervention: Plecanatide 3 mg
Number of subjects: 2370
Study: 29343156

Group type: EXPERIMENTAL
Intervention: Mobile phone-based hypertension self-management support system
Number of subjects: 20
Study: 29343167

Group type: EXPERIMENTAL
Intervention: Clinically assisted hydration, mouth care and usual other care
Number of subjects: 200

Group type: COMPARATOR
Intervention: Regular mouth care and usual other care
Number of subjects: 200
Study: 29343266

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 29343297

Group type: EXPERIMENTAL
Intervention: Contegra®
Number of subjects: 82

Group type: COMPARATOR
Intervention: Homograft
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: Contegra® and Homograft
Number of subjects: 82
Study: 29343534

Group type: EXPERIMENTAL
Intervention: hs-cTnT and hs-cTnI
Number of subjects: 3828

Group type: EXPERIMENTAL
Intervention: hs-cTnI
Number of subjects: 3828

Group type: EXPERIMENTAL
Intervention: hs-cTnT
Number of subjects: 3828
Study: 29343998

Group type: EXPERIMENTAL
Intervention: Pacemaker respiratory disturbance index (RDI)
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: Continuous positive airway pressure therapy
Number of subjects: 68
Study: 29344432

Group type: EXPERIMENTAL
Intervention: WT1 peptide vaccine with Montanide as an adjuvant
Number of subjects: 4

Group type: COMPARATOR
Intervention: Poly ICLC
Number of subjects: 4
Study: 29344726

Group type: EXPERIMENTAL
Intervention: Elbasvir 50 mg plus grazoprevir 100 mg once daily for 12 weeks
Number of subjects: 1070
Study: 29345044

Group type: EXPERIMENTAL
Intervention: TAK-063 at 0.3 mg/kg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: TAK-063
Number of subjects: 0
Study: 29346367

Group type: EXPERIMENTAL
Intervention: Albendazole (ABZ) administered orally
Number of subjects: 8
Study: 29346377

Group type: EXPERIMENTAL
Intervention: Community-wide mass drug administration (MDA) delivered door-to-door, twice annually for three years.
Number of subjects: 80000

Group type: COMPARATOR
Intervention: Standard-of-care MDA, typically annual school-based deworming.
Number of subjects: 80000

Group type: EXPERIMENTAL
Intervention: Community-wide MDA
Number of subjects: 80000
Study: 29346388

Group type: EXPERIMENTAL
Intervention: 18 mg ivermectin tablet
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: 36 mg ivermectin tablet
Number of subjects: 54

Group type: COMPARATOR
Intervention: Standard weight-based regimen (150–200 μg/kg)
Number of subjects: 54
Study: 29346478

Group type: EXPERIMENTAL
Intervention: Enasidenib (50 to 650 mg/d during dose-escalation; 100 mg/d during phase 1 expansion and phase 2)
Number of subjects: 281

Group type: EXPERIMENTAL
Intervention: Enasidenib
Number of subjects: 281

Group type: EXPERIMENTAL
Intervention: Systemic corticosteroids for management of IDH-DS
Number of subjects: 281
Study: 29346519

Group type: EXPERIMENTAL
Intervention: Cetuximab 400 mg/m2 loading dose in week 1 followed by 250 mg/m2 weekly and cisplatin 30 mg/m2 concurrent with 6 weeks of intensity-modulated radiotherapy (60-66 Gy in 30 daily fractions)
Number of subjects: 46
Study: 29346834

Group type: EXPERIMENTAL
Intervention: Ravidasvir (RDV) 200 mg once daily plus ritonavir-boosted danoprevir (DNVr) 100 mg/100 mg twice daily and oral ribavirin (RBV) 1000/1200 mg/day for 12 weeks
Number of subjects: 38
Study: 29346833

Group type: EXPERIMENTAL
Intervention: Ficlatuzumab in combination with Gefitinib
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 29347915

Group type: EXPERIMENTAL
Intervention: Self-reported current insulin use
Number of subjects: 498

Group type: EXPERIMENTAL
Intervention: Self-reported frequent non-severe hypoglycemia in the past year
Number of subjects: 498

Group type: EXPERIMENTAL
Intervention: Self-reported severe hypoglycemia in the past year
Number of subjects: 498

Group type: EXPERIMENTAL
Intervention: Being very worried about hypoglycemia at least occasionally
Number of subjects: 498

Group type: EXPERIMENTAL
Intervention: Being very worried about hypoglycemia at least occasionally (for family members)
Number of subjects: 498
Study: 29347947

Group type: EXPERIMENTAL
Intervention: Two sessions/week of knee-extensor strength exercise (three sets, 12 repetitions at 12 RM, per exercise session) for 12 weeks
Number of subjects: 140

Group type: EXPERIMENTAL
Intervention: Four sessions/week of knee-extensor strength exercise (three sets, 12 repetitions at 12 RM, per exercise session) for 12 weeks
Number of subjects: 140

Group type: EXPERIMENTAL
Intervention: Six sessions/week of knee-extensor strength exercise (three sets, 12 repetitions at 12 RM, per exercise session) for 12 weeks
Number of subjects: 140

Group type: COMPARATOR
Intervention: Control group (not explicitly mentioned in the abstract)
Number of subjects: 140
Study: 29347952

Group type: EXPERIMENTAL
Intervention: Quality collaborative interventions including interdisciplinary case analyses, external peer-reviews, hospital-wide staff education, and implementation of rapid response teams.
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Claims data analysis and risk-adjusted hospital mortality reporting.
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Quarterly quality reports focusing on risk-adjusted hospital mortality.
Number of subjects: 75
Study: 29347983

Group type: EXPERIMENTAL
Intervention: Internet-based support and coaching intervention for 8 weeks
Number of subjects: 16
Study: 29347987

Group type: EXPERIMENTAL
Intervention: Clinical and biological parameters at ICU discharge including N-terminal pro-B type natriuretic peptide, high-sensitive troponin I, bioactive-adrenomedullin, and soluble-ST2.
Number of subjects: 1570

Group type: EXPERIMENTAL
Intervention: Elevated biomarkers of cardiac and vascular failure at ICU discharge.
Number of subjects: 1570
Study: 29347993

Group type: EXPERIMENTAL
Intervention: Avelumab 10 mg/kg by 1-h intravenous infusion every 2 weeks until confirmed disease progression, unacceptable toxicity, or withdrawal.
Number of subjects: 88
Study: 29347991

Group type: EXPERIMENTAL
Intervention: Home-based physical exercise program using a rowing machine, three times a week for three months (experimental group)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Home-based physical exercise program
Number of subjects: 42
Study: 29348128

Group type: EXPERIMENTAL
Intervention: Pevonedistat (PEV) 20 or 30 mg/m² combined with azacitidine (AZA)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 29348179

Group type: EXPERIMENTAL
Intervention: Inhaled corticosteroids
Number of subjects: 0

Group type: COMPARATOR
Intervention: Cigarette smoking status
Number of subjects: 0
Study: 29349065

Group type: EXPERIMENTAL
Intervention: Omega-3 acids supplementation (2 g/day)
Number of subjects: 114

Group type: COMPARATOR
Intervention: Healthy individuals (control group)
Number of subjects: 114
Study: 29349545

Group type: EXPERIMENTAL
Intervention: Bare-metal stents (BMS) with clopidogrel 75 mg for 4 weeks
Number of subjects: 765

Group type: COMPARATOR
Intervention: Drug-eluting stents (DES) without HTPR with clopidogrel for 6 months
Number of subjects: 765

Group type: COMPARATOR
Intervention: Drug-eluting stents (DES) with HTPR with clopidogrel for 6 months
Number of subjects: 765
Study: 29349598

Group type: EXPERIMENTAL
Intervention: lumretuzumab (1000 mg in Cohort 1; 500 mg in Cohorts 2 and 3) plus pertuzumab (840 mg loading dose followed by 420 mg in Cohorts 1 and 2; 420 mg without loading dose in Cohort 3) plus paclitaxel (80 mg/m2) every 3 weeks
Number of subjects: 35
Study: 29350386

Group type: COMPARATOR
Intervention: VKAs (acenocoumarol, warfarin)
Number of subjects: 3528

Group type: COMPARATOR
Intervention: Dabigatran
Number of subjects: 3528

Group type: EXPERIMENTAL
Intervention: Rivaroxaban
Number of subjects: 3528

Group type: EXPERIMENTAL
Intervention: Lower doses of dabigatran and rivaroxaban
Number of subjects: 3528

Group type: COMPARATOR
Intervention: VKAs
Number of subjects: 3528

Group type: EXPERIMENTAL
Intervention: NOACs (dabigatran and rivaroxaban)
Number of subjects: 3528
Study: 29350463

Group type: EXPERIMENTAL
Intervention: Vemurafenib 720 mg BID
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Vemurafenib 960 mg BID
Number of subjects: 6
Study: 29350586

Group type: EXPERIMENTAL
Intervention: Exercise as a treatment for depression
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Media campaign
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: TREAD-UK trial results
Number of subjects: 0
Study: 29351649

Group type: EXPERIMENTAL
Intervention: Leptin levels in Fulani girls
Number of subjects: 98

Group type: EXPERIMENTAL
Intervention: Leptin levels in Fulani boys
Number of subjects: 98

Group type: EXPERIMENTAL
Intervention: Leptin levels in Wolof boys
Number of subjects: 98

Group type: COMPARATOR
Intervention: Schistosoma haematobium infection prevalence
Number of subjects: 98
Study: 29351667

Group type: EXPERIMENTAL
Intervention: 5 mg/kg/day benznidazole orally in two divided doses for 8 weeks
Number of subjects: 99
Study: 29351822

Group type: EXPERIMENTAL
Intervention: Group 4 (with OA and with OSA)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Group 1 (Control)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Group 3 (without OA and with OSA)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Group 2 (with OA and without OSA)
Number of subjects: 60
Study: 29351897

Group type: EXPERIMENTAL
Intervention: Intensive care after OHCA
Number of subjects: 50
Study: 29351900

Group type: EXPERIMENTAL
Intervention: Digital mental health interventions
Number of subjects: 18
Study: 29351982

Group type: EXPERIMENTAL
Intervention: Leukemia survivors
Number of subjects: 1025

Group type: COMPARATOR
Intervention: Controls
Number of subjects: 1025
Study: 29351986

Group type: EXPERIMENTAL
Intervention: Ruxolitinib (oral JAK1/2 inhibitor), at least six cycles administered to 9 patients (27.3%), more than six cycles to 6 patients (18.2%)
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Ruxolitinib (oral JAK1/2 inhibitor)
Number of subjects: 33
Study: 29352057

Group type: EXPERIMENTAL
Intervention: Flow Re-Direction Endoluminal Device (FRED)
Number of subjects: 103
Study: 29352572

Group type: EXPERIMENTAL
Intervention: Veliparib 250mg combined with carboplatin AUC 4 and gemcitabine 800mg/m
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Veliparib plus carboplatin/gemcitabine
Number of subjects: 75
Study: 29352703

Group type: EXPERIMENTAL
Intervention: Inotuzumab ozogamicin plus mini-hyper-CVD chemotherapy
Number of subjects: 52
Study: 29352719

Group type: EXPERIMENTAL
Intervention: Immunochemotherapy combinations (including bendamustine-containing regimens)
Number of subjects: 1494

Group type: EXPERIMENTAL
Intervention: Bendamustine-containing regimens
Number of subjects: 1494

Group type: EXPERIMENTAL
Intervention: Ibrutinib or idelalisib in the relapse/refractory setting
Number of subjects: 1494

Group type: EXPERIMENTAL
Intervention: Unfavorable-risk genetics, age ≥ 75 years, race, and treatment choice at enrollment
Number of subjects: 1494
Study: 29352732

Group type: EXPERIMENTAL
Intervention: Crizotinib 250 mg twice daily
Number of subjects: 44
Study: 29353109

Group type: EXPERIMENTAL
Intervention: Tacrolimus stopped at day +90
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: Tacrolimus stopped at day +60
Number of subjects: 102
Study: 29353339

Group type: EXPERIMENTAL
Intervention: Lightweight polypropylene mesh
Number of subjects: 363

Group type: COMPARATOR
Intervention: Heavyweight polypropylene mesh
Number of subjects: 363
Study: 29354050

Group type: EXPERIMENTAL
Intervention: Physical exercise intervention
Number of subjects: 0
Study: 29354720

Group type: EXPERIMENTAL
Intervention: Toric implantable collamer lens (TICL) implantation after corneal collagen crosslinking
Number of subjects: 24
Study: 29355075

Group type: EXPERIMENTAL
Intervention: Nivolumab plus ipilimumab
Number of subjects: 119
Study: 29355224

Group type: EXPERIMENTAL
Intervention: DMPA
Number of subjects: 7800

Group type: EXPERIMENTAL
Intervention: Copper T 380A intrauterine device
Number of subjects: 7800

Group type: EXPERIMENTAL
Intervention: Levonorgestrel implant
Number of subjects: 7800
Study: 29355412

Group type: EXPERIMENTAL
Intervention: Fluoride in office (drops/tablets and/or varnish) applied by a health care professional by age 1 y
Number of subjects: 1325

Group type: COMPARATOR
Intervention: Control group (children who did not receive fluoride in office)
Number of subjects: 1325
Study: 29355439

Group type: EXPERIMENTAL
Intervention: Minidose glucagon (150 μg, increased to 300 μg if needed)
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Hypoglycemia prediction algorithm
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Glucagon administration
Number of subjects: 7
Study: 29355904

Group type: EXPERIMENTAL
Intervention: Ingenol mebutate gel, 0.015% for face/scalp and 0.05% for trunk/extremities, applied for treatment of AK
Number of subjects: 77
Study: 29356347

Group type: EXPERIMENTAL
Intervention: EBFSS scale developed from Hughes' Breastfeeding Social Support Scale, validated at 1 and 3 months postpartum.
Number of subjects: 475
Study: 29356365

Group type: EXPERIMENTAL
Intervention: TRIP (risk network tracing)
Number of subjects: 1252

Group type: COMPARATOR
Intervention: IBBS (respondent-driven sampling)
Number of subjects: 1252

Group type: COMPARATOR
Intervention: Outreach Testing
Number of subjects: 1252

Group type: EXPERIMENTAL
Intervention: TRIP (recently-infected participants' networks)
Number of subjects: 1252

Group type: EXPERIMENTAL
Intervention: TRIP (longer-term infected participants' networks)
Number of subjects: 1252
Study: 29356607

Group type: EXPERIMENTAL
Intervention: Combined aerobic and resistance exercise (supervised moderate-to-vigorous 65% to 85% of heart rate maximum, three times per week for 16 weeks)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Combined aerobic and resistance exercise
Number of subjects: 100

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 100
Study: 29356832

Group type: EXPERIMENTAL
Intervention: Short DAPT (≤6 months)
Number of subjects: 517

Group type: COMPARATOR
Intervention: Long DAPT (12 months)
Number of subjects: 517
Study: 29357099

Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy (CBT) for mean 21 weeks (sd 5, range 8-24)
Number of subjects: 30
Study: 29357718

Group type: EXPERIMENTAL
Intervention: Dulaglutide 0.75 mg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Insulin glargine
Number of subjects: 0
Study: 29357821

Group type: EXPERIMENTAL
Intervention: Dining Environment Audit Protocol (DEAP)
Number of subjects: 639
Study: 29357826

Group type: EXPERIMENTAL
Intervention: Chair muscle strength training twice a week for 12 weeks
Number of subjects: 64

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 64
Study: 29357841

Group type: EXPERIMENTAL
Intervention: ZIKV RNA presence testing in various body fluids (blood, urine, semen, vaginal secretion/menstrual blood, rectal swab, oral fluids, tears, sweat, breast milk)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Co-infection testing for dengue, Chikungunya, HIV, hepatitis B and C, syphilis
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Immunological response testing (including IgM and IgG)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Plaque reduction neutralization test for ZIKV and dengue
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: ZIKV culture and RNA sequencing
Number of subjects: 0
Study: 29357861

Group type: EXPERIMENTAL
Intervention: Stemless humeral head arthroplasty
Number of subjects: 73
Study: 29357940

Group type: EXPERIMENTAL
Intervention: Intervention group (psychological preparation and distraction strategy)
Number of subjects: 57

Group type: COMPARATOR
Intervention: Baseline group (no intervention)
Number of subjects: 57
Study: 29358182

Group type: EXPERIMENTAL
Intervention: Blinatumomab
Number of subjects: 0
Study: 29358183

Group type: EXPERIMENTAL
Intervention: Lenalidomide-based therapy
Number of subjects: 288
Study: 29358426

Group type: EXPERIMENTAL
Intervention: Initial diffusion-weighted imaging (DWI) lesions
Number of subjects: 122

Group type: EXPERIMENTAL
Intervention: Cortical grey matter (cGM) lesions
Number of subjects: 122

Group type: EXPERIMENTAL
Intervention: DWI lesions area size
Number of subjects: 122

Group type: EXPERIMENTAL
Intervention: Acute FLAIR-visibility
Number of subjects: 122

Group type: EXPERIMENTAL
Intervention: Overall DWI-positive patients
Number of subjects: 122